文献速递白血病造血干细胞移植与细胞治疗

源自细胞周期蛋白E的两个独特HLA-A*0201限制性肽作为白血病免疫治疗靶点

Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia.
PubMed 文献 · Leukemia · 2020-01-06

该研究探索细胞周期蛋白E作为白血病免疫治疗新靶点。通过RT-PCR和Western blot发现cyclin E1和E2在血液恶性肿瘤中高表达,鉴定出两个HLA-A*0201结合九肽CCNE1M和CCNE2L,均可诱导肽特异性CTL并特异性杀伤白血病细胞。在异基因造血干细胞移植后白血病患者中,CCNE1M和CCNE2L CTL增加并与理想临床结局相关。

要点

  • cyclin E1和E2在血液恶性肿瘤中高表达,可作为免疫治疗候选靶点。
  • CCNE1M和CCNE2L两个HLA-A*0201限制性九肽可诱导肽特异性CTL。
  • 肽特异性CTL可特异性杀伤白血病细胞,且在异基因HSCT后患者中增加并与理想临床结局相关。

核心结论

  • 细胞周期蛋白E1和E2是白血病免疫治疗的潜在靶点。

研究设计与样本

  • 研究采用逆转录聚合酶链反应和蛋白质印迹分析检测cyclin E1和E2在血液恶性肿瘤中的表达,并鉴定HLA-A*0201结合肽及评估肽特异性CTL功能。

主要发现

  • cyclin E1和E2在血液恶性肿瘤中高表达。
  • 鉴定出两个HLA-A*0201结合九肽CCNE1M(来自cyclin E1)和CCNE2L(来自cyclin E2),两者均能诱导肽特异性CTL。
  • 肽特异性CTL能特异性杀伤白血病细胞。
  • 在异基因造血干细胞移植后白血病患者中,CCNE1M和CCNE2L CTL增加,并与理想临床结局相关。

临床怎么用

  • cyclin E1和E2来源的HLA-A*0201限制性肽CCNE1M和CCNE2L可作为白血病免疫治疗的候选靶点,尤其在与异基因造血干细胞移植联合时可能增强抗白血病免疫应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy targeting leukemia-associated antigens has shown promising results. Because of the heterogeneity of leukemia, vaccines with a single peptide have elicited only a limited immune response. Targeting several peptides together elicited peptide-specific cytotoxic T lymphocytes (CTLs) in leukemia patients, and this was associated with clinical responses. Thus, the discovery of novel antigens is essential. In the current study, we investigated cyclin E as a novel target for immunotherapy. Cyclin E1 and cyclin E2 were found to be highly expressed in hematologic malignancies, according to reverse transcription polymerase chain reaction and western blot analysis. We identified two HLA-A*0201 binding nonameric peptides, CCNE1M from cyclin E1 and CCNE2L from cyclin E2, which both elicited the peptide-specific CTLs. The peptide-specific CTLs specifically kill leukemia cells. Furthermore, CCNE1M and CCNE2L CTLs were increased in leukemia patients who underwent allogeneic hematopoietic stem cell transplantation, and this was associated with desired clinical outcomes. Our findings suggest that cyclin E1 and cyclin E2 are potential targets for immunotherapy in leukemia.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. He H, Kondo Y, Ishiyama K, et al. Two unique HLA-A*0201 restricted peptides derived from cyclin E as immunotherapeutic targets in leukemia. Leukemia. 2020. PMID: 31908357. doi:10.1038/s41375-019-0698-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。